Dr. Zhihua Yao 姚志华
Chief Physician
Department of Integrated Traditional Chinese and Western Medicine Oncology, Henan Cancer Hospital, Zhengzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of malignant lymphoma, metastatic lymph node tumors, gastrointestinal tumors, lung cancer, breast cancer, ovarian cancer, soft tissue sarcoma, and common pediatric tumors using chemotherapy, targeted immunotherapy, and CAR-T cell therapy.
Dr. Yao is a Chief Physician and ward head in the Department of Comprehensive Lymphoma Internal Medicine at Henan Cancer Hospital. Holding a medical doctorate, Dr. Yao was a visiting scholar at MD Anderson Cancer Center. With extensive experience in lymphoma and other malignancies, Dr. Yao has published over 20 papers and received multiple provincial research awards.
Professional roles
- Vice Chair, Lymphoma Professional Committee, China Health Promotion Association
- Member, Targeted Therapy Professional Committee, Chinese Women Doctors Association
- Member, Integrated Traditional Chinese and Western Medicine Lymphoma Professional Committee, China Anti-Cancer Association
- Member, Lymphoma Professional Committee, Henan Anti-Cancer Association
Name order: in Chinese the family name comes first (Yao Zhihua). Papers usually list the name as Zhihua Yao or Yao Z.
Selected publications
32 papers on PubMed matched by name and affiliation; 5 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Oncol Pharm Pract, 2022 (senior author): Multiple rechallenges with anti-PD-1 immunotherapy in patients with checkpoint inhibitor-related pneumonitis: A report of two cases. PubMed 35037786
- Cancer Manag Res, 2021 (senior author): Primary Testicular Lymphoma with Central Nervous System Relapse Was Successfully Treated by a Chemo-Free Regimen: A Case Report and Literature Review. PubMed 35002326
- Front Oncol, 2020 (senior author): Durable Response to Sintilimab and Chidamide in a Patient With Pegaspargase- and Immunotherapy-Resistant NK/T-Cell Lymphoma: Case Report and Literature Review. PubMed 33363038
- Cancer Manag Res, 2020 (senior author): A Trial of the Safety and Efficacy of Chemotherapy Plus Anlotinib vs Chemotherapy Alone as Second- or Third-Line Salvage Treatment for Advanced Non-Small Cell Lung Cancer. PubMed 32547218
- Tumour Biol, 2017 (first author): MMP-2 together with MMP-9 overexpression correlated with lymph node metastasis and poor prognosis in early gastric carcinoma. PubMed 28621235
- Zhonghua Zhong Liu Za Zhi, 2014 (first author): [Efficacy and safety of fixed dose rate gemcitabine infusion in combination with docetaxel in patients with relapsed/refractory soft tissue sarcoma]. PubMed 25327662
- Zhongguo Yi Xue Ke Xue Yuan Xue Bao, 2013 (first author): [Inhibitory effects of celecoxib combined with capecitabine on H22 hepatoma mice and its mechanism]. PubMed 23987495
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion